| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by investing activities | 12,612 | -23,876 |
| Payment of liability for in-licensing agreement and other | 9,240 | - |
| Proceeds from other liabilities and exercise of stock options | 19,207 | 11,653 |
| Payment of contingent consideration and other | - | 9,058 |
| Net cash provided by financing activities | 9,967 | 2,595 |
| Effect of exchange rate changes on cash and cash equivalents | 807 | 1,351 |
| Decrease in cash and cash equivalents | -73,166 | -63,888 |
| Cash and cash equivalents at beginning of period | 183,615 | - |
| Cash and cash equivalents at end of period | 110,449 | - |
AbCellera Biologics Inc. (ABCL)
AbCellera Biologics Inc. (ABCL)